NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE:GSK).
Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=134093&from=3
CLASS PERIOD: February 5, 2020 to August 14, 2022
ALLEGATIONS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators.” GSK also stated that it was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European …
